Skip to main content

Table 2 Response of Renca-MUC1 tumors to radiation and vaccine and tumor rechallenge

From: Radiotherapy and MVA-MUC1-IL-2 vaccine act synergistically for inducing specific immunity to MUC-1 tumor antigen

  aResponders/Cured bImmune to Rechallenge cIFN-γ Mean Spots ± SD  
  # Mice/Total Percent
Control 0/36 0% N/A N/A
Vaccine 0/7 0% N/A N/A
Radiation 2/43 4% 0/6 N/A
Rad + Empty Vector 3/20 15% 3/3 140.4 ± 29.4
Rad + Vaccine (Schedule 1) 11/45 24% 9/9 156.4 ± 24.6
Vaccine + Rad (Schedule 2) 17/29 58% 7/8 152.6 ± 24.1
  1. Data were compiled from three independent experiments
  2. aResponders/Cured: Responders were characterized by inhibition of tumor growth or complete tumor regression
  3. bImmune to rechallenge: Responding and non-responding mice were challenged with 1x105 Renca-MUC1 cells injected in the left flank contralateral to the Renca-MUC1 primary tumor on day 40–60
  4. cIFN-γ: Splenocytes were obtained from mice at 3-4 weeks after tumor rechallenge, stimulated with Renca-MUC1 cells in vitro and tested for production of IFN-γ in an ELISPOT assay